PapersFlow Research Brief
Neuroendocrine Tumor Research Advances
Research Guide
What is Neuroendocrine Tumor Research Advances?
Neuroendocrine Tumor Research Advances encompass epidemiological studies, classification systems, management strategies, and therapeutic developments for neuroendocrine tumors, particularly pancreatic neuroendocrine tumors, including somatostatin receptor-based imaging and therapy, MEN1 syndrome, peptide receptor radionuclide therapy, genetic mutations, and survival analysis.
Research on neuroendocrine tumors includes 92,262 works focused on epidemiology, classification, management, and treatment. Studies examine pancreatic neuroendocrine tumors, somatostatin receptors, MEN1 syndrome, peptide receptor radionuclide therapy, and survival outcomes. Incidence and prevalence of neuroendocrine tumors are rising, with improved survival for gastrointestinal and pancreatic cases.
Topic Hierarchy
Research Sub-Topics
Pancreatic Neuroendocrine Tumors
This sub-topic covers incidence, grading, staging, and prognostic factors specific to pNETs, including functional vs. non-functional types. Researchers analyze registries and biomarkers for risk stratification.
Somatostatin Receptor Imaging
This sub-topic evaluates DOTATOC/PET-CT and other SSTR-based modalities for detection, staging, and therapy selection in NETs. Researchers compare sensitivity, specificity, and clinical utility.
Peptide Receptor Radionuclide Therapy
This sub-topic assesses 177Lu-DOTATATE efficacy, toxicity, and predictors of response in advanced NETs. Researchers report phase III trials, dosimetry, and long-term outcomes.
MEN1 Syndrome
This sub-topic investigates genetic screening, multigland disease patterns, and surveillance in MEN1-associated NETs. Researchers study phenotype-genotype correlations and surgical strategies.
Neuroendocrine Tumor Epidemiology
This sub-topic tracks incidence trends, survival rates, and geographic variations using SEER and national registries. Researchers identify rising diagnoses and demographic disparities.
Why It Matters
Neuroendocrine tumor research advances patient outcomes through targeted therapies and improved detection. "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors" (Strosberg et al., 2017) showed 177Lu-Dotatate extended progression-free survival compared to high-dose octreotide LAR in advanced midgut cases, with a higher response rate and preliminary overall survival benefit. "Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States" (Dasari et al., 2017) reported rising incidence and prevalence, alongside better survival for distant-stage gastrointestinal and pancreatic neuroendocrine tumors due to therapeutic progress. Epidemiology from "One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States" (Yao et al., 2008) analyzed 35,825 cases to identify prognostic factors, informing management guidelines.
Reading Guide
Where to Start
"One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States" (Yao et al., 2008) provides foundational epidemiology and prognosis data from 35,825 cases, serving as an accessible entry to tumor characteristics and incidence.
Key Papers Explained
"One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States" (Yao et al., 2008) established baseline epidemiology, which Dasari et al. (2017) in "Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States" updated with rising incidence and survival gains. Strosberg et al. (2017) in "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors" built on these by demonstrating peptide receptor radionuclide therapy efficacy, extending progression-free survival in midgut cases.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Focus on peptide receptor radionuclide therapy outcomes from phase 3 trials and survival trends in pancreatic cases, as survival improvements continue for distant-stage disease per Dasari et al. (2017). No recent preprints or news available.
Papers at a Glance
Frequently Asked Questions
What are the key epidemiological trends in neuroendocrine tumors?
Incidence and prevalence of neuroendocrine tumors are rising in the United States, possibly due to early detection and stage migration. "Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States" (Dasari et al., 2017) documented improved survival over time, particularly for distant-stage gastrointestinal and pancreatic neuroendocrine tumors. These changes reflect advances in therapies.
How does 177Lu-Dotatate perform in midgut neuroendocrine tumors?
177Lu-Dotatate treatment resulted in longer progression-free survival and higher response rates than high-dose octreotide LAR in advanced midgut neuroendocrine tumors. "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors" (Strosberg et al., 2017) provided phase 3 trial evidence of these outcomes, with preliminary overall survival benefits. This peptide receptor radionuclide therapy targets somatostatin receptors.
What prognostic factors were identified for neuroendocrine tumors?
Analysis of 35,825 neuroendocrine tumor cases in the United States identified epidemiology and prognostic factors. "One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States" (Yao et al., 2008) used Surveillance, Epidemiology, and End Results data to examine these factors. Neuroendocrine tumors produce various hormones and were previously understudied.
What is the survival impact of therapies in pancreatic neuroendocrine tumors?
Survival for pancreatic neuroendocrine tumors has improved, especially at distant stages. "Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States" (Dasari et al., 2017) linked this to therapy improvements. Research emphasizes somatostatin receptor-based approaches and peptide receptor radionuclide therapy.
How many cases were analyzed in major neuroendocrine tumor epidemiology studies?
One study examined 35,825 neuroendocrine tumor cases from the United States. "One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States" (Yao et al., 2008) provided comprehensive data on incidence and prognosis. This marks a thorough examination after a century since the term carcinoid.
Open Research Questions
- ? What genetic mutations drive progression in pancreatic neuroendocrine tumors?
- ? How do somatostatin receptor profiles influence therapy response in MEN1 syndrome-associated neuroendocrine tumors?
- ? Which combinations of peptide receptor radionuclide therapy with other agents optimize survival in advanced gastroenteropancreatic neuroendocrine neoplasms?
- ? What factors explain rising incidence and prevalence of neuroendocrine tumors beyond detection improvements?
- ? How do tumor classification systems predict outcomes in survival analysis for neuroendocrine tumors?
Recent Trends
Incidence and prevalence of neuroendocrine tumors steadily rose per "Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States" (Dasari et al., 2017), with survival improving for gastrointestinal and pancreatic cases, especially distant-stage.
The field includes 92,262 works on epidemiology, management, somatostatin receptor therapies, and peptide receptor radionuclide therapy.
No recent preprints or news reported changes.
Research Neuroendocrine Tumor Research Advances with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neuroendocrine Tumor Research Advances with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers